Study Data from Newcastle University Centre for Cancer Update Understanding of Prostate Cancer (Sialylation Inhibition Can Partially Revert Acquired Resistance to Enzalutamide in Prostate Cancer Cells).

A recent study conducted by researchers at Newcastle University Centre for Cancer in the United Kingdom has found that sialylation inhibition can partially reverse acquired resistance to enzalutamide therapy in prostate cancer cells. Enzalutamide is a commonly used treatment for castrate-resistant prostate cancer, but patients often develop secondary resistance to the drug. The study discovered that prostate cancer cells with acquired resistance to enzalutamide have increased levels of a2,6-sialylated N-glycans, and inhibiting sialylation can partially reverse this resistance. The findings suggest that combining enzalutamide therapy with sialic acid blockade may be a promising approach for treating advanced prostate cancer. [Extracted from the article]